Lv65
2190 积分 2024-10-16 加入
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
1天前
待确认
Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
1天前
待确认
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
1天前
待确认
Identification of rare recurrent FNBP1::JAK2 fusion in myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions
14天前
已完结
Identification of a novel fusion TBL1XR1–PDGFRB in a patient with acute myeloid leukemia harboring the DEK–NUP214 fusion and clinical response to dasatinib
1个月前
已完结
Coexistence of t(5;17)/NPM1-RARA and t(9;22)/BCR-ABL1 in chronic myeloid leukemia at initial diagnosis
1个月前
已完结
Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib
1个月前
已完结
Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia
1个月前
已完结
Prognostic significance of GATA2 in patients with MDS/AML: a systematic review and meta-analysis
1个月前
已完结
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
1个月前
已完结
皖公网安备34019202002308
